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Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is an 68 effective therapeutic agent for non-small cell lung cancer with EGFR mutations (Harada et 69 al., 2011; Mok et al., 2009) . It can cause severe acute pneumonitis in some patients. 70
Characteristics of patients who developed interstitial pneumonia included old age, poor 71 performance status, a history of smoking, and preexisting interstitial pneumonia (Harada et 72 al., 2011; Kudoh et al., 2008) . 73
Injuries to respiratory epithelium and alveolar epithelial cells are regarded as the initial 74 phenomena of various respiratory illnesses, such as acute respiratory distress syndrome, 75 interstitial pneumonia, and chronic obstructive pulmonary disease. 76
Neutrophil elastase is a protease produced by neutrophils. Excessive neutrophil elastase 77 can cause lung tissue damage by direct cytotoxicity to endothelial and epithelial cells and 78 by degradation of key structural elements of connective tissue, such as elastin, collagen, 79 and proteoglycan (Yamada et al., 2011; Lee and Downey, 2001) . 80
Sivelestat, a small molecule (529 Da), is a neutrophil elastase inhibitor developed and 81 produced by Ono Pharmaceutical Company in Japan (Aikawa et al., 2011) . In the animal 82 models of acute lung injury (ALI), the beneficial effects of sivelestat have been reported in 83 bleomycin-induced inflammation and streptococcus pneumonia (Yuan et al., 2014; 84 Yamada et al., 2011) . A phase 3 study in Japan demonstrated that sivelestat improved the 85 investigator assessment of pulmonary function and significantly reduced the duration of 86 intensive care required for patients with ALI associated with systemic inflammatory 87 response syndrome (SIRS) (Tamakuma et al., 2004) . In 2002, sivelestat was approved in 88 Japan for the treatment of ALI associated with SIRS (Aikawa et al., 2011) . After approval, 89 a phase 4 study indicated that it contributed to early weaning from mechanical ventilation 90 (Aikawa et al., 2011) . The beneficial effects of sivelestat have also been reported in several 91 other models, including lipopolysaccharide (LPS)-induced lung inflammation, ozone-92 induced airway response, and bleomycin-induced pulmonary fibrosis (Yuan et al., 2014; 93 Matsumoto et al., 1999; Takemasa et al., 2012) . 94
Pulmonary stem cells are important for tissue recovery. The club cell is a type of 95 pulmonary stem cell found in the distal airway. Stem cell abnormality is considered to 96 promote chronic lung injury and lung fibrosis (Harada et al., 2011; Gazdhar et al., 2007) . 97 Naphthalene has club cell-selective cytotoxicity (Harada et al., 2011; Van Winkle et al., 98 1995; Stripp et al., 1995) . Therefore, we previously used a naphthalene-induced lung 99 4 injury model as an animal model containing a risk factor of gefitinib-induced pneumonia. 100
We found that gefitinib administration after naphthalene treatment prolonged ALI with 101 neutrophil infiltration on day 14. Laser capture microdissection and microarray analysis of 102 the terminal bronchial epithelial cells showed upregulation of the genes included-S100a8, 103 S100a6, Stfa3, Trim23, and Mug1, which are known to participate in inflammatory cell 104 chemotaxis, activation, and migration (Harada et al., 2011; Raquil et al., 2008; Ozato et al., 105 2008) . Although the precise mechanisms involved remain unclear, gefitinib treatment 106 prolonged lung inflammation by upregulating neutrophil chemoattractant genes from 107 peripheral epithelial cells. Therefore, we hypothesize that sivelestat plays a protective role 108 against gefitinib-induced lung injury by inhibiting neutrophilic inflammation. 109
110

RESULTS: 111
Sivelestat improved the survival rate of gefitinib-induced pneumonitis in mice 112
The administration of 300-mg/kg gefitinib with 150-mg/kg sivelestat following 113 naphthalene significantly improved the survival rate on day 14 compared with that of 114 300 mg/kg gefitinib following naphthalene ( Figure 2 ). 115
116
Sivelestat ameliorated the loss of body weight of gefitinib-induced pneumonitis in 117 mice 118
We measured mice body weight to determine the general influence of ALI. Weight loss is 119 a good marker for the severity of naphthalene-induced lung injury (Harada et al., 2011; 120 Verschoyle et al., 1997) . On day 7, the body weights of mice treated with naphthalene 121 alone were significantly decreased; however, by day 14, the body weights returned to the 122 level of the control injected with corn oil. On day 14, body weights of mice treated with 123 250 mg/kg gefitinib following naphthalene remained significantly decreased compared 124 with that of mice treated with naphthalene alone, whereas the body weights of mice treated 125 with 250 mg/kg gefitinib and 150 mg/kg sivelestat following naphthalene were 126 significantly increased compared with that of mice treated with 250 mg/kg gefitinib 127 following naphthalene ( Figure 3 We used histologic cell analysis to examine the degree of inflammatory cell infiltration. 133
Naphthalene alone induced neutrophil infiltration on day 7 but not on day 14 in the lung 134 tissue, as previously described (Harada et al., 2011) . The administration of 250 mg/kg 135 gefitinib following naphthalene aggravated neutrophil infiltration and induced alveolar 136 hemorrhage on day 14 ( Figure 4A ). In contrast, the administration of 250 mg/kg gefitinib 137 with 150 mg/kg sivelestat following naphthalene significantly decreased the pathologic 138 grade compared with that of 250 mg/kg gefitinib following naphthalene ( Figure 4B ). 139
BALF analysis 140
On day 14, the number of neutrophils, total cell count, and protein concentration in BALF 141 of mice treated with 250 mg/kg gefitinib following naphthalene were significantly 142 increased compared with those of mice treated with naphthalene alone. On day 14, the 143 administration of 250 mg/kg gefitinib and 150 mg/kg sivelestat following naphthalene 144 significantly decreased the number of neutrophils, total cell count, and protein 145 concentration in BALF compared with that with 250 mg/kg gefitinib following 146 naphthalene ( Figure 5) . 147
In addition, the administration of 250 mg/kg gefitinib and 150 mg/kg sivelestat following 148 naphthalene significantly decreased the level of IL-8 ( Figure 6A ) and neutrophil elastase 149 activity ( Figure 6B ) in BALF compared with those resulting from the administration of 150 250 mg/kg gefitinib following naphthalene. 151
152
DISCUSSION 153
As we reported previously, the presumed sequence of the mechanism of gefitinib-154 naphthalene pneumonitis is as follows: 1) the upregulation of neutrophil chemoattractant 155 genes in bronchiolar epithelial cells; 2) neutrophil migration into alveolar space and 156 interstitial tissues, and; 3) release of neutrophil elastase from neutrophils, resulting in lung 157 tissue damage. 158 IL-8 is produced by alveolar epithelial cell line (A549), airway epithelial cells, and 159 inflammatory cells, such as macrophages and neutrophils. IL-8 is a well-known 160 neutrophilic chemoattractant. Some studies have reported that gefitinib induces the 161 production of IL-8 from alveolar epithelial cell line (A549). Neutrophil elastase induces 162 the release of IL-8 from bronchial epithelial cells (Yamada et al., 2011; Nakamura et al., 163 1992) , which in turn recruits additional neutrophils. Our study indicated that 164 administration of sivelestat decreased neutrophil elastase, which in turn inhibited the level 165 6 of IL-8 in gefitinib-naphthalene-induced pneumonitis. In other words, sivelestat treatment 166 could halt the negative spiral of lung injury. A limitation of the current study was that we 167 could not identify the IL-8 producing cells targeted by sivelestat; therefore, further studies 168 are required. 169 A significant reduction in the number of club cells has been observed in the airway 170 epithelium of chronic tobacco smokers (Nomori et al., 1994) . The naphthalene-induced 171 club cell injury in a mice model may be representative of patients at a high risk of 172 gefitinib-induced pneumonitis. This suggests that the presence of peripheral airway 173 damage may increase the susceptibility of patients with lung cancer to interstitial 174 pneumonia during treatment with gefitinib. 175
In conclusion, we demonstrated a treatment strategy for ALI caused by gefitinib. Currently, 176 new generation EGFR-TKIs, such as afatinib and osimertinib, are used for treating non-177 small cell lung cancer with EGFR mutations. It is well known that the new generation 178 EGFR-TKIs also induce pneumonitis; therefore, the current study should be repeated for 179 the new generation EFGR-TKIs. 180
181
MATERIALS AND METHODS: 182
Animal treatment 183
The experiments were approved by the Committee on Ethics Regarding Animal 184 Experiments of Kyushu University. C57BL/6 female mice (7 weeks old; SLC, Inc, 185 Shizuoka Japan) were used in all experiments. 186 Naphthalene (Wako Pure Chemical Industries, Osaka, Japan) was injected 187 intraperitoneally on day 0 (200 mg/kg). Gefitinib (Caymann Chemical, Arizona, USA) 188 stirred into 1% Tween 80 (Wako) was daily administered orally on days −1 to 13. We 189 administrated gefitinib at two doses: 1) 250 mg/kg as a tolerated dose and 2) 300 mg/day 190 as the 50% lethal dose (LC 50 ). The neutrophil elastase inhibitor sivelestat (Ono 191 Pharmaceutical, Osaka, Japan) in saline was daily injected intraperitoneally on days 1 to 192 13 (150 mg/kg). A scheme of the administration schedule is shown in Figure 1 . 193 194 Histopathological evaluation 195 Histopathology was performed as previously described (Harada et al., 2011; Hamada et al., 196 2008) . The bronchoalveolar lavage (BAL) method and analysis was performed as previously 206 described (Harada et al., 2011; Hamada et al., 2008) . , S., Ogawa, M., Aikawa, N., Kubota, T., Hirasawa, H., Ishizaka, A.,  293   Taenaka, N., Hamada, C., Matsuoka, S. and Abiru, T. (2004) . Relationship 294 between neutrophil elastase and acute lung injury in humans. Pulm. Pharmacol. 295 Ther. 17, [271] [272] [273] [274] [275] [276] [277] [278] [279] Van Winkle, L. S., Buckpitt, A. R., Nishio, S. J., Isaac, J. M. and Plopper, C. G. 297 (1995) Survival study of mice with the administration of 300 mg/kg gefitinib and 150 mg/kg 319 sivelestat following naphthalene improved the survival rate compared with that of 320 300 mg/kg gefitinib following naphthalene (n = 10). *P < 0.05. 321 Body weights of mice treated with naphthalene alone were significantly decreased on 323 day 7; however, by day 14, the body weights returned to the level of the control. On day 14, 324 the body weights of mice treated with 250 mg/kg gefitinib following naphthalene remained 325 significantly decreased compared with that of mice treated with naphthalene alone, 326
whereas the body weights of mice treated with 250 mg/kg gefitinib and 150 mg/kg 327 11 sivelestat following naphthalene were significantly increased compared with those of mice 328 at treated with 250 mg/kg gefitinib following naphthalene. 329
Compared with control group at the same point (n = 7). *P < 0.05, **P < 0.01. 330 and was decreased by administration of 250 mg/kg gefitinib and 150 mg/kg sivelestat 348 following naphthalene (n = 5). *P < 0.05. 349 (B) Neutrophil elastase was increased by the administration of 250 mg/kg gefitinib 350 following naphthalene and was decreased by administration of 250 mg/kg gefitinib and 351 150 mg/kg sivelestat following naphthalene (n = 5). **P < 0.01. 352
